Asparaginase Toxicities: Identification and Management in Patients With Acute Lymphoblastic Leukemia
| Autor: | Sharon Bergeron, Van Huynh |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Asparaginase Adolescent Lymphoblastic Leukemia medicine.medical_treatment Antineoplastic Agents Drug Hypersensitivity 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine medicine Humans In patient Child Adverse effect Intensive care medicine Hyperbilirubinemia General Environmental Science Chemotherapy business.industry Infant Cancer Venous Thromboembolism Precursor Cell Lymphoblastic Leukemia-Lymphoma medicine.disease Survival Analysis Thrombosis Pancreatitis chemistry Child Preschool Hyperglycemia 030220 oncology & carcinogenesis General Earth and Planetary Sciences business 030215 immunology |
| Zdroj: | Clinical Journal of Oncology Nursing. 21:E248-E259 |
| ISSN: | 1538-067X 1092-1095 |
| DOI: | 10.1188/17.cjon.e248-e259 |
| Popis: | Background Acute lymphoblastic leukemia (ALL) is a common cancer in children, and outcomes have greatly improved because of the refinement of multiagent chemotherapy regimens that include intensified asparaginase therapy. Asparaginase, a cornerstone of modern pediatric chemotherapy regimens for ALL and asparaginase-containing protocols, is increasingly used in adolescent and adult patients historically treated with asparaginase-free regimens. . Objectives This article is an overview of commonly encountered asparaginase- associated toxicities and offers recommendations for treatment management. . Methods A literature review was conducted, reviewing asparaginase and common toxicities, specifically hypersensitivity, pancreatitis, thrombosis, hyperbilirubinemia, and hyperglycemia. . Findings The rapid identification and management of common asparaginase-associated adverse events can reduce symptom severity and limit potential interruptions to therapy, possibly improving outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|